Fundraising Fox
Valius
Founded 2025 · 11 employees on LinkedIn · 1 known investors
Find your way into Valius
323 people in our graph can introduce you to the Valius team.
Sign up to see every warm intro you have to Valius
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Valius team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Valius is a molecular oncology company that develops tools to understand cancer cell behavior and enable targeted drug development and personalized therapies. It serves clinical and pharmaceutical organizations focused on improving cancer treatment outcomes.
Founders & leadership
Valius was founded in 2025 by Sarah Hesse.
EL
Investors · 1
Related companies · 4
Talus BioTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Vesalius TherapeuticsVesalius Therapeutics develops a computational platform that identifies distinct disease subtypes within common diseases like heart failure, diabetes, and Alzheimer's by analyzing patient data and gene circuits, then uses proprietary cell-based models to discover targeted drug candidates. The company serves patients with prevalent chronic diseases using artificial intelligence, genomics, and patient-derived experimental models.
Alveus TherapeuticsAlveus Therapeutics develops next-generation metabolic and obesity therapies, including its lead asset ALV-100 (in Phase 2) and a preclinical amylin pipeline of peptides, oral small molecules, and novel formats aimed at sustainable weight loss with better tolerability. The company uses human genetic data and clinical expertise to select drug targets in the obesity treatment landscape.
Companies working in the same space as Valius.
Frequently asked questions
- What does Valius do?
- Valius is a molecular oncology company that develops tools to understand cancer cell behavior and enable targeted drug development and personalized therapies. It serves clinical and pharmaceutical organizations focused on improving cancer treatment outcomes.
- Who founded Valius?
- Valius was founded by Sarah Hesse in 2025.
- Who are Valius's investors?
- Valius's investors include Compound.